Kazia Therapeutics (KZIA) Competitors $3.93 +0.34 (+9.47%) Closing price 05/1/2025 03:50 PM EasternExtended Trading$3.90 -0.04 (-0.89%) As of 05/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. SYBX, QNTM, ABP, LSB, ORGS, TXMD, BGXX, AFMD, NERV, and RLYBShould you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Synlogic (SYBX), Quantum Biopharma (QNTM), Abpro (ABP), Lakeshore Biopharma (LSB), Orgenesis (ORGS), TherapeuticsMD (TXMD), Bright Green (BGXX), Affimed (AFMD), Minerva Neurosciences (NERV), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. Kazia Therapeutics vs. Synlogic Quantum Biopharma Abpro Lakeshore Biopharma Orgenesis TherapeuticsMD Bright Green Affimed Minerva Neurosciences Rallybio Synlogic (NASDAQ:SYBX) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership. Do insiders & institutionals believe in SYBX or KZIA? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are held by institutional investors. 3.0% of Synlogic shares are held by insiders. Comparatively, 1.0% of Kazia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, SYBX or KZIA? Synlogic has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Is SYBX or KZIA more profitable? Kazia Therapeutics' return on equity of 0.00% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -207.84% -114.81% Kazia Therapeutics N/A N/A N/A Do analysts rate SYBX or KZIA? Kazia Therapeutics has a consensus price target of $57.50, suggesting a potential upside of 1,363.10%. Given Kazia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kazia Therapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer SYBX or KZIA? Synlogic received 251 more outperform votes than Kazia Therapeutics when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 52.98% of users gave Kazia Therapeutics an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% Kazia TherapeuticsOutperform Votes8052.98% Underperform Votes7147.02% Does the media favor SYBX or KZIA? In the previous week, Synlogic and Synlogic both had 2 articles in the media. Synlogic's average media sentiment score of 1.44 equaled Kazia Therapeutics'average media sentiment score. Company Overall Sentiment Synlogic Positive Kazia Therapeutics Positive Which has preferable earnings & valuation, SYBX or KZIA? Kazia Therapeutics has higher revenue and earnings than Synlogic. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$8K1,688.61-$57.28M-$2.51-0.46Kazia Therapeutics$2.31M1.71-$17.56MN/AN/A SummaryKazia Therapeutics beats Synlogic on 8 of the 13 factors compared between the two stocks. Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricKazia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.96M$6.85B$5.54B$7.93BDividend YieldN/A2.97%5.09%4.22%P/E RatioN/A7.3222.5518.54Price / Sales1.71241.43395.25103.29Price / CashN/A65.8538.1834.62Price / Book-1.996.486.764.25Net Income-$17.56M$143.41M$3.22B$248.18M7 Day Performance7.23%2.58%1.37%1.03%1 Month Performance-1.75%5.00%2.77%2.70%1 Year Performance-72.18%-3.72%15.59%4.05% Kazia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIAKazia Therapeutics3.7826 of 5 stars$3.93+9.5%$57.50+1,363.1%-73.4%$3.96M$2.31M0.0012Positive NewsSYBXSynlogic2.4429 of 5 stars$1.06+0.0%N/A-39.2%$12.40M$8,000.00-0.2580Short Interest ↓Positive NewsGap DownQNTMQuantum BiopharmaN/A$6.24-1.0%N/AN/A$11.98MN/A-0.40N/AUpcoming EarningsABPAbproN/A$0.23-10.5%$4.00+1,631.6%N/A$11.97M$122,000.000.0015Gap UpHigh Trading VolumeLSBLakeshore Biopharma1.3845 of 5 stars$1.28-7.2%N/AN/A$11.91M$672.27M0.00773Short Interest ↓Positive NewsGap UpORGSOrgenesisN/A$2.48+13.2%N/AN/A$11.90M$662,000.000.00150Gap DownTXMDTherapeuticsMD1.766 of 5 stars$1.00-1.4%N/A-26.1%$11.53M$1.76M0.00420Upcoming EarningsAnalyst ForecastBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownAFMDAffimed3.5115 of 5 stars$0.70-4.0%$13.50+1,818.2%-79.4%$11.33M$877,000.000.00200NERVMinerva Neurosciences3.7984 of 5 stars$1.66+3.8%$5.00+201.2%-27.7%$11.19MN/A-3.779Negative NewsRLYBRallybio2.3204 of 5 stars$0.27+6.0%$10.00+3,672.2%-84.1%$11.03M$636,000.00-0.1740Upcoming EarningsGap Up Related Companies and Tools Related Companies SYBX Alternatives QNTM Alternatives ABP Alternatives LSB Alternatives ORGS Alternatives TXMD Alternatives BGXX Alternatives AFMD Alternatives NERV Alternatives RLYB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KZIA Stock Free KZIA Stock Alerts